Elements of cancer immunity and the cancer-immune set point - PubMed (original) (raw)
Review
. 2017 Jan 18;541(7637):321-330.
doi: 10.1038/nature21349.
Affiliations
- PMID: 28102259
- DOI: 10.1038/nature21349
Review
Elements of cancer immunity and the cancer-immune set point
Daniel S Chen et al. Nature. 2017.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Similar articles
- Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Baumeister SH, et al. Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25. Annu Rev Immunol. 2016. PMID: 26927206 Review. - Mechanisms of immune escape in the cancer immune cycle.
Tang S, Ning Q, Yang L, Mo Z, Tang S. Tang S, et al. Int Immunopharmacol. 2020 Sep;86:106700. doi: 10.1016/j.intimp.2020.106700. Epub 2020 Jun 23. Int Immunopharmacol. 2020. PMID: 32590316 Review. - Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM, Chen DS. Kim JM, et al. Ann Oncol. 2016 Aug;27(8):1492-504. doi: 10.1093/annonc/mdw217. Epub 2016 May 20. Ann Oncol. 2016. PMID: 27207108 Review. - TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
Manieri NA, Chiang EY, Grogan JL. Manieri NA, et al. Trends Immunol. 2017 Jan;38(1):20-28. doi: 10.1016/j.it.2016.10.002. Epub 2016 Oct 25. Trends Immunol. 2017. PMID: 27793572 Review. - Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ, Sullivan RJ. Mooradian MJ, et al. Future Oncol. 2017 Aug;13(18):1649-1663. doi: 10.2217/fon-2017-0117. Epub 2017 Aug 4. Future Oncol. 2017. PMID: 28776423 Review.
Cited by
- Current status of immunotherapy for non-small cell lung cancer.
Yang T, Xiong Y, Zeng Y, Wang Y, Zeng J, Liu J, Xu S, Li LS. Yang T, et al. Front Pharmacol. 2022 Oct 13;13:989461. doi: 10.3389/fphar.2022.989461. eCollection 2022. Front Pharmacol. 2022. PMID: 36313314 Free PMC article. Review. - The crucial roles of N6-methyladenosine (m6A) modification in the carcinogenesis and progression of colorectal cancer.
Fang Z, Hu Y, Hu J, Huang Y, Zheng S, Guo C. Fang Z, et al. Cell Biosci. 2021 Apr 9;11(1):72. doi: 10.1186/s13578-021-00583-8. Cell Biosci. 2021. PMID: 33836813 Free PMC article. Review. - A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer.
Liu C, Gong J, Yu H, Liu Q, Wang S, Wang J. Liu C, et al. Front Oncol. 2021 Feb 24;11:544339. doi: 10.3389/fonc.2021.544339. eCollection 2021. Front Oncol. 2021. PMID: 33718125 Free PMC article. - Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.
Manitz J, Gerhold-Ay A, Kieslich P, Shah P, Mrowiec T, Tyroller K. Manitz J, et al. Cancer Med. 2024 Jun;13(12):e7411. doi: 10.1002/cam4.7411. Cancer Med. 2024. PMID: 38924353 Free PMC article. Clinical Trial. - Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy.
Liu X, Zhao J, Li X, Lao F, Fang M. Liu X, et al. Vaccines (Basel). 2022 Sep 17;10(9):1552. doi: 10.3390/vaccines10091552. Vaccines (Basel). 2022. PMID: 36146629 Free PMC article. Review.
References
- J Clin Invest. 2011 Aug;121(8):3109-19 - PubMed
- Science. 2015 Apr 3;348(6230):80-6 - PubMed
- Nat Immunol. 2013 Oct;14(10):1014-22 - PubMed
- Curr Genomics. 2008 Sep;9(6):394-408 - PubMed
- J Clin Invest. 2015 Sep;125(9):3401-12 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials